Optimizing and Qualifying Reporter Gene Bioassays for Immune Checkpoint Receptors
Promega webinars are free and are presented at various times on the webinar date for easy global access. Select your preferred time and click register.
Get Involved With Our Webinars
Personalized Seminars for Your Lab
Jey Cheng is a R&D group leader in bioassay development at Promega Corporation. Dr. Cheng's group focuses on developing MoA-based reporter gene bioassays using engineered cell lines. Prior to joining Promega, Jey was an assistant professor of Biochemistry & Molecular Biology at Mayo Clinic College of Medicine, where she also completed postdoctoral Kendall-Mayo Fellowship in Biochemistry. She received her PhD in Cell Biology from Shanghai Institute of Cell Biology through a joint PhD program by Germany Max-Planck Society and Chinese Academy of Sciences.
Zhijie Jey Cheng, PhD
Sr Research Scientist
- See speaker bio
Tuesday, March 28, 2017
Reporter gene assays for functional screening and development of antibody drug candidates are gaining popularity due to the significant advantages they offer over traditional methods that rely on human primary immune cells. We will discuss development of a series of MoA-based reporter gene bioassays for antibodies targeting co-inhibitory receptors, co-stimulatory receptors and combination bioassays that target immune checkpoint receptors.
The use of antibodies targeting immune checkpoints for the treatment of cancers is gaining momentum. However, the functional screening and development of drug candidates often relies on the use of human primary immune cells which use methods that are tedious and highly variable, and are therefore technically challenging to implement. Reporter gene assays offer the advantage to be robust, extremely fast, and easy to implement and transfer between global sites. They are widely adopted in the drug development environment. In this webinar, we will discuss the development of a series of MoA-based reporter gene bioassays for antibodies targeting immune inhibitory receptors (PD-1, CTLA-4, TIGIT, LAG3), immune co-stimulatory receptors (4-1BB, OX40, GITR, CD40, HVEM, CD27), or combination bioassays targeting two immune checkpoint receptors (PD-1+TIGIT, PD-1+CTLA-4, PD-1+LAG3). We will show case studies on assay design and development, assay optimization with Thaw-and-Use cells, and assay qualification (repeatability, intermediate precision, specifically and linearity). Please join us to learn more about how reporter gene bioassays can facilitate the antibody screening and development in drug discovery.